- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01330303
SECOTEX® (Tamsulosin Hydrochloride) Bioequivalence Study Brazil - Fed Admin
Randomized, Two-period, Cross-over, Bioequivalence Study on Tamsulosin Hydrochloride 0,4 mg Prolonged Release Hard Gelatin Capsule Versus SECOTEX® (Tamsulosin Hydrochloride) 0,4 mg Prolonged Release Hard Gelatin Capsule Healthy Male Volunteers Under Fed Conditions
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
It will be an open-label, randomized, laboratory-blind, crossover study with 02 treatments, 02 sequences, and 02 periods, in which the volunteers receive, in each period, the test formulation or the reference formulation, under fed conditions.
The treatment's sequence attributed to each volunteer on the study period is determined by a randomization list, which is generated by PROC PLAN from SAS version 9.1.3 system.
The formulations will be administered as a single oral dose followed by blood collections between, at least, 3 to 5 half-lives. The treatment's periods may obey a minimum interval of 7 half lives between them (period for drug's whole elimination by the organism).
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
São Paulo
-
Campinas, São Paulo, Brazil
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
EXCLUSION CRITERIA:
- The volunteer has a known hypersensitivity to the study drug (tamsulosin hydrochloride) or to compounds chemically related;
- History or presence of hepatic or gastrointestinal illnesses, or other condition that interferes over the drug's absorption, distribution, excretion or metabolism;
- History of hepatic, renal, pulmonary, gastrointestinal, epileptic, hematologic or psychiatric illness; hypo or hypertension of any etiologic that needs pharmacologic treatment; has history or had myocardial infarction, angina and/or heart insufficiency;
- Non-recommended electrocardiographic findings, according investigator criteria;
- The results of the laboratory exams are out of the values considered as normal according this protocol's rules, unless that they are considered as clinically irrelevant by the investigator;
- Volunteer is a smoker;
- The volunteer ingests more than 5 cups of coffee or tea a day;
- Has history of alcohol or drugs abuse;
- History of serious adverse reactions or hypersensitivity to any drug;
- Use of any regular drug within the 02 weeks that preceded study's initiation or treatment within the 03 previous months, that preceded study's initiation, with any drug that presents toxic, or volunteer consumed inductive drugs and/or enzymatic inhibitor (CYP450 - hepatic), within the 04 weeks that preceded the study's initiation;
- Volunteer was hospitalized for any reason within the 08 weeks of the beginning of the study's first period of treatment and the post study assessment date;
- Participation in any experimental study or ingestion of any experimental drug within the 06 previous months;
- Volunteer consumed alcohol in 48 hours prior to the admission to the study or consumed foods or beverages that contain grapefruit until 07 days previous to each study period.
INCLUSION CRITERIA:
- Male;
- Age between 18 and 50 years;
- Body mass index ≥ 19 and ≤28,5;
- Good health conditions or without significant illness, by judgment of a legally qualified professional, according the rules defined in Protocol, and according the following evaluations: clinical history, pressure and pulse measures, physical and psychological exam, ECG, and additional laboratory exams;
- Capable to understand the study's nature and aim, including the risks and adverse effects and with intention to cooperate with the researcher and to act in compliance with the requirements of the whole assay; this will be confirmed by the Informed Consent's signature.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: tamsulosin - Reference
Reference drug administration followed by Test drug administration
|
tamsulosin hydrochloride 0,4 mg (Synthon BV)
SECOTEX® (tamsulosin hydrochloride) 0,4 mg (Boehringer Ingelheim)
|
Active Comparator: tamsulosin - Test
Test drug administration followed by Reference drug administration
|
tamsulosin hydrochloride 0,4 mg (Synthon BV)
SECOTEX® (tamsulosin hydrochloride) 0,4 mg (Boehringer Ingelheim)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUC 0-t
Time Frame: Day 1 (day that blood collections started) to Day 4 (Period 1) and Days 8 to 11 (Period 2)
|
The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC).
The AUC from time 0 (prior to administration of medication) to time t (the time of the last quantifiable concentration) was calculated using the trapezoidal method.
This method consists of the sum of the trapezoids' areas, determined by the collection times and their concentrations.
The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption.
ng, nanograms; ml, milliliter.
|
Day 1 (day that blood collections started) to Day 4 (Period 1) and Days 8 to 11 (Period 2)
|
AUC0-infinity
Time Frame: Day 1 (day that blood collections started) to Day 4 (Period 1) and Days 8 to 11 (Period 2)
|
The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC).
The AUC from time 0 (prior to administration of medication) to infinity (the time of complete elimination of the drug) was calculated using the trapezoidal method.
This method consists of the sum of the trapezoids' areas, determined by the collection times and their concentrations.
The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption.
|
Day 1 (day that blood collections started) to Day 4 (Period 1) and Days 8 to 11 (Period 2)
|
Cmax
Time Frame: Day 1 (day that blood collections started) to Day 4 (Period 1) and Days 8 to 11 (Period 2)
|
Cmax is defined as the maximum or "peak" concentration of a drug observed after its administration.
Cmax is one of the parameters of particular use in estimating the bioavailability of drugs, by measuring the total amount of drug absorbed.
|
Day 1 (day that blood collections started) to Day 4 (Period 1) and Days 8 to 11 (Period 2)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 114073
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostatic Hyperplasia
-
GlaxoSmithKlineCompletedBenign Prostatic Hyperplasia
-
St. Joseph's Healthcare HamiltonOntario Ministry of Health and Long Term CareCompletedBenign Prostatic HyperplasiaCanada
-
Assiut UniversityNot yet recruiting
-
NeoTract, Inc.Not yet recruitingBenign Prostatic Hyperplasia
-
Assiut UniversityNot yet recruitingBenign Prostatic Hyperplasia
-
Second Affiliated Hospital, School of Medicine,...RecruitingBenign Prostatic HyperplasiaChina
-
Jewish General HospitalNot yet recruitingBenign Prostatic Hyperplasia
-
Zenflow, Inc.RecruitingBenign Prostatic HyperplasiaAustralia, New Zealand
-
REMD Medical TechnologyRenJi Hospital; Tongji Hospital; Qilu Hospital of Shandong University; Sun Yat-Sen... and other collaboratorsCompletedBenign Prostatic HyperplasiaChina
-
Bioaraba Health Research InstituteCompletedBenign Prostatic HyperplasiaSpain
Clinical Trials on Test formulation
-
Alcon ResearchCompleted
-
Eli Lilly and CompanyCompletedHealthy ParticipantsSingapore
-
Astellas Pharma Global Development, Inc.CompletedHealthy VolunteersUnited States
-
Assembly BiosciencesCompletedChronic Hepatitis BUnited States
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompleted
-
GlaxoSmithKlineCompletedProstatic HyperplasiaBrazil
-
Janssen Research & Development, LLCCompleted
-
PfizerCompleted